New York, March 27, 2024 - PRISM MarketView - PAVmed Inc. (NASDAQ: PAVM), a diversified medical device company, experienced a notable surge in its stock price after outperforming earnings expectations.
Highlights:
PAVmed’s Q4 Non-GAAP EPS of -$1.33 surpassed estimates by $0.47, with revenue climbing to $1.05 million, indicating a substantial year-over-year increase.
Year-end cash and equivalents stood at $19.6 million, down from $39.7 million, reflecting strategic investments and operational expenditures.
Lucid Diagnostics showcased robust growth with a 33% sequential revenue increase, driven by the EsoGuard product’s performance.
The launch of the PMX incubator and strategic efforts to secure independent financing highlight PAVmed’s pivot towards enhancing shareholder value through focused subsidiary development and commercialization.
PAVmed closed as the leader of the PRISM MedDevices Index with shares up 32%.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities
PRISM MarketView - Social Media (X)